Ribophorin II expression status is a predictive marker for drug resistance, cell proliferation, and motility in various cancers, and higher ribophorin II expression is associated with poor patient prognosis (Honma et al., 2008; Kurashige et al., 2012; Fujita et al., 2015; Yuan et al., 2015). Here, RPN2 is linked to cancer.